Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ADALIMUMAB Cause Systemic lupus erythematosus? 11,880 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 11,880 reports of Systemic lupus erythematosus have been filed in association with ADALIMUMAB (YUSIMRY). This represents 2.4% of all adverse event reports for ADALIMUMAB.

11,880
Reports of Systemic lupus erythematosus with ADALIMUMAB
2.4%
of all ADALIMUMAB reports
1,884
Deaths
2,815
Hospitalizations

How Dangerous Is Systemic lupus erythematosus From ADALIMUMAB?

Of the 11,880 reports, 1,884 (15.9%) resulted in death, 2,815 (23.7%) required hospitalization, and 2,188 (18.4%) were considered life-threatening.

Is Systemic lupus erythematosus Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ADALIMUMAB. However, 11,880 reports have been filed with the FAERS database.

What Other Side Effects Does ADALIMUMAB Cause?

Drug ineffective (71,926) Pain (37,514) Arthralgia (35,592) Rheumatoid arthritis (29,817) Fatigue (29,420) Injection site pain (28,679) Headache (19,891) Nausea (19,299) Rash (18,690) Pain in extremity (18,319)

What Other Drugs Cause Systemic lupus erythematosus?

METHOTREXATE (9,350) INFLIXIMAB (9,071) ABATACEPT (8,944) HYDROXYCHLOROQUINE (8,867) RITUXIMAB (8,819) PREDNISONE (8,799) LEFLUNOMIDE (8,669) TOCILIZUMAB (8,656) FOLIC ACID (8,360) CERTOLIZUMAB PEGOL (8,212)

Which ADALIMUMAB Alternatives Have Lower Systemic lupus erythematosus Risk?

ADALIMUMAB vs ADALIMUMAB-AACF ADALIMUMAB vs ADALIMUMAB-AATY ADALIMUMAB vs ADALIMUMAB-ADAZ ADALIMUMAB vs ADALIMUMAB-ADBM ADALIMUMAB vs ADALIMUMAB-AFZB

Related Pages

ADALIMUMAB Full Profile All Systemic lupus erythematosus Reports All Drugs Causing Systemic lupus erythematosus ADALIMUMAB Demographics